# The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects

> **NCT00767598** · PHASE1 · COMPLETED · sponsor: **Inje University** · enrollment: 21 (actual)

## Conditions studied

- Pharmacokinetics of Three PDE5Is
- Healthy Subjects
- Genetic Polymorphic CYP3A5

## Interventions

- **DRUG:** phosphodiesterase type 5 inhibitor
- **DRUG:** phosphodiesterase type 5 inhibitor
- **DRUG:** phosphodiesterase type 5 inhibitor

## Key facts

- **NCT ID:** NCT00767598
- **Lead sponsor:** Inje University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2007-12
- **Final completion:** 2008-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2008-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00767598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00767598, "The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00767598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*